Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to ...

The company announced a new partnership with Eli Lilly’s LillyDirect pharmacy ... to receive prescriptions for Zepbound in single-dose vial form directly through the WeightWatchers app, which ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical company.

The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers ... Our innovative, trusted spectrum of solutions provides members ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

(Reuters) -Eli Lilly on Thursday downplayed ... slightly below analysts' expectations of $2.33 billion. Lilly in February cut the price for vials of Zepbound by $50 or more and expanded the ...